UA86937C2 - Композиция, которая содержит лактат и калий, и ее применение - Google Patents

Композиция, которая содержит лактат и калий, и ее применение

Info

Publication number
UA86937C2
UA86937C2 UAA200511417A UAA200511417A UA86937C2 UA 86937 C2 UA86937 C2 UA 86937C2 UA A200511417 A UAA200511417 A UA A200511417A UA A200511417 A UAA200511417 A UA A200511417A UA 86937 C2 UA86937 C2 UA 86937C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
containing pharmaceutical
lactate containing
per liter
millimoles per
Prior art date
Application number
UAA200511417A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ксавье М. Леверв
Мустафа Икбал
Original Assignee
Инноджен Калбайотек Питии Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инноджен Калбайотек Питии Лтд filed Critical Инноджен Калбайотек Питии Лтд
Publication of UA86937C2 publication Critical patent/UA86937C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Изобретение касается фармацевтической композиции, которая содержит от 250 до 2400 миллимоль на литр молочной кислоты или лактата и от 2 до 10 миллимоль на литр калиевого катиона и необязательно от 2 до 5 миллимоль на литр кальциевого катиона. Изобретение также касается применения такой композиции в фармацевтике.
UAA200511417A 2003-05-01 2004-03-22 Композиция, которая содержит лактат и калий, и ее применение UA86937C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01

Publications (1)

Publication Number Publication Date
UA86937C2 true UA86937C2 (ru) 2009-06-10

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200511417A UA86937C2 (ru) 2003-05-01 2004-03-22 Композиция, которая содержит лактат и калий, и ее применение

Country Status (31)

Country Link
US (1) US20080125488A1 (ru)
EP (2) EP1617834B1 (ru)
JP (1) JP5037937B2 (ru)
KR (1) KR101076059B1 (ru)
CN (1) CN1777416B (ru)
AR (1) AR043670A1 (ru)
AT (1) ATE340568T1 (ru)
AU (1) AU2004233904B2 (ru)
BR (1) BRPI0409867A (ru)
CA (1) CA2523740C (ru)
CY (1) CY1105880T1 (ru)
DE (1) DE602004002585T2 (ru)
DK (1) DK1617834T3 (ru)
EA (2) EA013846B1 (ru)
ES (1) ES2274438T3 (ru)
HK (1) HK1085942A1 (ru)
IL (1) IL171721A (ru)
MA (1) MA27845A1 (ru)
MX (1) MXPA05011532A (ru)
MY (1) MY140382A (ru)
NO (1) NO20055652L (ru)
NZ (1) NZ543201A (ru)
PL (1) PL1617834T3 (ru)
PT (1) PT1617834E (ru)
SG (1) SG160217A1 (ru)
SI (1) SI1617834T1 (ru)
TN (1) TNSN05275A1 (ru)
TW (1) TWI290045B (ru)
UA (1) UA86937C2 (ru)
WO (1) WO2004096204A1 (ru)
ZA (1) ZA200509684B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648598A1 (en) * 2006-04-03 2007-10-11 Innogene Kalbiotech Pte Ltd Lactate and calcium containing pharmaceutical composition and uses thereof
WO2008119518A1 (en) 2007-03-30 2008-10-09 Laccure Ab Use of oligomers of lactic acid in the treatment of gynaecological disorders
PT2410981T (pt) 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
MX2011009956A (es) * 2009-03-26 2012-01-27 Pulmatrix Inc Formulaciones de citrato de calcio y lactato de calcio para la modificacion de las propiedades biofisicas del revestimiento mucosal.
EP2448571B1 (en) 2010-08-30 2013-06-12 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
AU2011308865B2 (en) 2010-09-29 2017-01-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
EP2621488B1 (en) 2010-09-29 2018-11-07 Pulmatrix Operating Company, Inc. Cationic dry powders
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
CN104661539B (zh) * 2012-08-01 2016-10-12 普拉克生物化学有限公司 乳酸粉末及其制备方法
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9500657B2 (en) 2012-10-25 2016-11-22 Run Them Sweet Llc Formulations containing labels for medical diagnostics
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
EP2754356A1 (en) 2013-01-15 2014-07-16 Purac Biochem N.V. Improved nisin production process
EP2769630B1 (en) 2013-02-26 2016-04-27 Purac Biochem N.V. Improved nisin production process
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
WO2015069961A1 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel prodrug salts
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
EP3481216B2 (en) 2016-07-07 2024-03-06 DSM IP Assets B.V. Process for obtaining a rapeseed protein isolate and protein isolate thereby obtained
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
WO2020163654A1 (en) * 2019-02-06 2020-08-13 Paul Leo Mcgrane Biologically modified vascular grafts for improved bypass surgery outcomes
EP4093507A4 (en) * 2020-01-24 2024-02-28 Barkey, Daniel, Q. WEIGHT LOSS COMPOSITIONS AND METHODS
WO2023114375A2 (en) * 2021-12-16 2023-06-22 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6776887A (en) * 1985-12-18 1987-07-15 Veech, R.L. Fluid therapy with l-lactate and/or pyruvate anions
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
DK0701455T3 (da) * 1993-06-04 2001-06-18 Biotime Inc Plasmalignende opløsning
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
NZ543201A (en) 2007-05-31
US20080125488A1 (en) 2008-05-29
AU2004233904A1 (en) 2004-11-11
EA200801073A1 (ru) 2008-08-29
TWI290045B (en) 2007-11-21
IL171721A (en) 2012-05-31
DK1617834T3 (da) 2007-02-05
BRPI0409867A (pt) 2006-05-16
DE602004002585T2 (de) 2007-10-25
CN1777416B (zh) 2012-11-07
EA013846B1 (ru) 2010-08-30
EA200501675A1 (ru) 2006-06-30
WO2004096204A1 (en) 2004-11-11
NO20055652L (no) 2006-02-01
EP1617834B1 (en) 2006-09-27
PL1617834T3 (pl) 2007-02-28
CY1105880T1 (el) 2011-02-02
EP1759695A1 (en) 2007-03-07
TW200423923A (en) 2004-11-16
CA2523740C (en) 2012-05-15
SG160217A1 (en) 2010-04-29
MA27845A1 (fr) 2006-04-03
AR043670A1 (es) 2005-08-03
TNSN05275A1 (en) 2007-07-10
EA010948B1 (ru) 2008-12-30
CA2523740A1 (en) 2004-11-11
HK1085942A1 (en) 2006-09-08
CN1777416A (zh) 2006-05-24
MXPA05011532A (es) 2006-05-31
EP1617834A1 (en) 2006-01-25
DE602004002585D1 (de) 2006-11-09
AU2004233904B2 (en) 2009-11-12
PT1617834E (pt) 2007-01-31
JP2006525324A (ja) 2006-11-09
ZA200509684B (en) 2007-03-28
MY140382A (en) 2009-12-31
SI1617834T1 (sl) 2007-02-28
KR20050119701A (ko) 2005-12-21
ATE340568T1 (de) 2006-10-15
KR101076059B1 (ko) 2011-10-21
ES2274438T3 (es) 2007-05-16
JP5037937B2 (ja) 2012-10-03
NO20055652D0 (no) 2005-11-30

Similar Documents

Publication Publication Date Title
TNSN05275A1 (en) Lactate containing pharmaceutical composition and uses thereof
HK1084404A1 (en) Muteins of tear lipocalin
MY143771A (en) Low ph aerated products
MX2007007189A (es) Prodrogas de compuestos de 2,4-pirimidindiamina y sus usos.
IL172364A (en) Variant of vii or viia factor at gla site
MXPA05010682A (es) Compuestos novedosos.
HK1102427A1 (en) Compositions comprising strontium and vitamin d and uses thereof
WO2005105110A3 (en) Doxepin analogs and methods of use thereof
TW200514772A (en) Novel tetrahydropyridine derivatives
TW200616960A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
GEP20135735B (en) Pharmaceutical compositions of rosuvastatin calcium
GB0511269D0 (en) Sustained release preparation of pro-insulin C-peptide
TW200715961A (en) Herbicide composition
MY164917A (en) Lactate containing pharmaceutical composition and uses thereof
SI1716128T1 (sl) Substituirane 4,5,6,7-tetrahidro-benzotiazol-2-ilaminske spojine
MY144204A (en) Aquoues olanexidine solution, method of preparing the same, and disinfectant
AU2003267359A1 (en) Sweet containing calcium
TW200613271A (en) Crystalline forms of 1,24(s)-dihydroxy vitamin d2
IL154007A0 (en) Soluble fertilizer compositions comprising calcium and/or magnesium phosphates
MY138502A (en) Novel alkansulfonamides as endothelin antagonists
WO2004026245A8 (en) Substituted phosphonate compounds having bone anabolic activity
WO2004022657A3 (de) Verstärkung der resorption von substanzen über die haut und schleimhaut
WO2004071381A3 (de) Arzneimittel enthaltend substituierte 2-aryl-aminoessigsäure-verbindungen und/oder substituierte 2-heteroaryl-aminoessigsäure-verbindungen
WO2005054174A3 (de) Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes